Literature DB >> 2510168

An immunoregulatory function for the CD8 molecule.

D R Kaplan1, J E Hambor, M L Tykocinski.   

Abstract

The molecular details of immunoregulatory phenomena associated with CD8+ T lymphocytes have not been clearly elucidated. We tested the hypothesis that the cell surface glycoprotein CD8 is itself essential in mediating the inhibitory effects associated with CD8+ T cells. For this purpose we utilized a T-cell clonal pair, consisting of a human CD8+ T-cell clone and a specific CD8- phenocopy of this clone obtained via antisense RNA mutagenesis, to modulate allogeneic responses in vitro. Our findings indicate that the expression of the CD8 molecule by the inhibitory cells is essential for down-regulation of both allogeneic proliferation and generation of cytotoxicity in mixed lymphocyte cultures. These results define an immunomodulatory function for the CD8 molecule and provide insights into the molecular basis of immunosuppression.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2510168      PMCID: PMC298312          DOI: 10.1073/pnas.86.21.8512

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  17 in total

1.  Use of an Epstein-Barr virus episomal replicon for anti-sense RNA-mediated gene inhibition in a human cytotoxic T-cell clone.

Authors:  J E Hambor; C A Hauer; H K Shu; R K Groger; D R Kaplan; M L Tykocinski
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

2.  Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis.

Authors:  O Lider; T Reshef; E Beraud; A Ben-Nun; I R Cohen
Journal:  Science       Date:  1988-01-08       Impact factor: 47.728

3.  Possible association between IL-2 receptors and class I HLA molecules on T cells.

Authors:  M Sharon; J R Gnarra; M Baniyash; W J Leonard
Journal:  J Immunol       Date:  1988-11-15       Impact factor: 5.422

4.  Cell-cell adhesion mediated by CD8 and MHC class I molecules.

Authors:  A M Norment; R D Salter; P Parham; V H Engelhard; D R Littman
Journal:  Nature       Date:  1988-11-03       Impact factor: 49.962

5.  Effects of anti-class I antibodies on proliferation of murine T lymphocytes.

Authors:  H C O'Neill
Journal:  Cell Immunol       Date:  1988-03       Impact factor: 4.868

Review 6.  Veto cells.

Authors:  P J Fink; R P Shimonkevitz; M J Bevan
Journal:  Annu Rev Immunol       Date:  1988       Impact factor: 28.527

7.  Epstein-Barr virus episome-based promoter function in human myeloid cells.

Authors:  C A Hauer; R R Getty; M L Tykocinski
Journal:  Nucleic Acids Res       Date:  1989-03-11       Impact factor: 16.971

8.  CD3 pathway of T-cell activation. II. Role of HLA-class I molecules in early events.

Authors:  R Schwab; M E Weksler; C Russo
Journal:  Cell Immunol       Date:  1988-09       Impact factor: 4.868

9.  Direct evidence for binding of CD8 to HLA class I antigens.

Authors:  Y Rosenstein; S Ratnofsky; S J Burakoff; S H Herrmann
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

10.  Functional consequences of anti-sense RNA-mediated inhibition of CD8 surface expression in a human T cell clone.

Authors:  J E Hambor; M L Tykocinski; D R Kaplan
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

View more
  6 in total

Review 1.  Treatment of an autoimmune disease with "classical" T cell veto: a proposal.

Authors:  U D Staerz; Y Qi
Journal:  J Clin Immunol       Date:  1999-07       Impact factor: 8.317

Review 2.  Antigen-presenting cell engineering. The molecular toolbox.

Authors:  M L Tykocinski; D R Kaplan; M E Medof
Journal:  Am J Pathol       Date:  1996-01       Impact factor: 4.307

3.  Inhibition of cytotoxic alloreactivity by human allogeneic mononuclear cells: evidence for veto function of CD2+ cells.

Authors:  G Raddatz; A Deiwick; T Sato; H J Schlitt
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

Review 4.  New designs for cancer vaccine and artificial veto cells: an emerging palette of protein paints.

Authors:  Mark L Tykocinski; Aoshuang Chen; Jui-Han Huang; Matthew C Weber; Guoxing Zheng
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

5.  AKR.H-2b lymphocytes inhibit the secondary in vitro cytotoxic T-lymphocyte response of primed responder cells to AKR/Gross murine leukemia virus-induced tumor cell stimulation.

Authors:  R F Rich; W R Green
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

6.  Clone-specific T cell receptor antagonists of major histocompatibility complex class I-restricted cytotoxic T cells.

Authors:  S C Jameson; F R Carbone; M J Bevan
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.